CP
JAZZ icon

CenterBook Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

CenterBook Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
+11,733
New +$2.57M 0.14% 166
2026
Q1 		– Sell
-30,104
Closed -$5.12M – 708
2025
Q4 		$5.12M Buy
+30,104
New +$4.62M 0.25% 100

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

CenterBook Partners's JAZZ Position: Q2 2026 in Review

CenterBook Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 11,733 shares worth $2.83M. The stake represents 0.14% of the portfolio and ranks #166 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in JAZZ as recently as Q4 2025.

CenterBook Partners first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.12M in Q4 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • CenterBook Partners held 11,733 shares of Jazz Pharmaceuticals worth $2.83M as of Q2 2026.
  • Jazz Pharmaceuticals was a new CenterBook Partners position in Q2 2026.
  • Jazz Pharmaceuticals made up 0.14% of CenterBook Partners's portfolio in Q2 2026, its #166 holding.
  • CenterBook Partners first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • CenterBook Partners's Jazz Pharmaceuticals position peaked at $5.12M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.